Last reviewed · How we verify
NCT05343832
Detection Evaluation of a Novel Blood-based DNA Methylation Assay in Early-stage Hepatocellular Carcinoma Patients
trial in Liver Cancer in 4,816 participants. Status unknown.
5 March 2023
Quick facts
| Lead sponsor | Genetron Health |
|---|---|
| Status | Status unknown |
| Study type | OBSERVATIONAL |
| Enrollment | 4,816 |
| Start date | 29 November 2021 |
| Primary completion | 5 March 2023 |
| Estimated completion | 25 April 2023 |
| Sites | 9 locations across China |
Conditions studied
- Liver Cancer — all drugs for Liver Cancer →
Sponsor
Genetron Health
Who can join
Eligibility, any sex, with Liver Cancer. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
This trail is a multi-center,prospective observational study aimed to detect early-stage Hepatocellular Carcinoma by a Novel Blood-based DNA Methylation Assay(named Genetron HCC Methylation PCR Kit ). The accuracy of the kit will also be evaluated . The trail will be enroll approximately 4816 participants, including participants with HCC or benign diseases, and high risk factors for liver cancer.
Publications & conference data
1 peer-reviewed publication reference this trial (live from Europe PMC):
-
Risk stratification and early detection biomarkers for precision HCC screening.
Lee YT, Fujiwara N, Yang JD, Hoshida Y. · · 2023 · cited 90× · PMID 36082510 · DOI 10.1002/hep.32779
Verify or expand the search:
- PubMed search for NCT05343832
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other recruiting trials for Liver Cancer
Currently open trials in the same condition.
- NCT07295275 — Safety and Efficacy of Transarterial ICG Fluorescence-Guided Laparoscopic Anatomical Liver Resection · recruiting
- NCT07410494 — Biomarker-Guided Allogeneic Single-Target or Dual-Target CAR-NK Cell Therapy for Advanced Solid Tumors · Phase 1, PHASE2 · recruiting
- NCT07295340 — Diagnostic Accuracy of Folate-Targeted NIR-II Carbon Dots for Ex Vivo HCC Detection · recruiting
- NCT07504367 — Large Language Models Assist in Tumor MDT · NA · recruiting
- NCT07447050 — Riluzole For Preventing Cognitive Dysfunction in Ca Pts Receiving Chemo (REFOCUS): Pilot Trial · Phase 2 · recruiting
Other Genetron Health trials
Trials by the same sponsor.
- NCT05494853 — Novel Biomarker Assay for Biomarker Assay for HCC Detection · unknown
- NCT05395429 — Clinical Evaluation of Genetron TERT/BRAF PCR Kit in Thyroid Cancer Patients · unknown
- NCT05400018 — Clinical Evaluation of Genetron D842V PCR Kit in GIST Patients · completed
- NCT05023746 — Clinical Evaluation of Genetron Lung Cancer Panel in Non-small Cell Lung Cancer Patients · completed
- NCT05100602 — Clinical Evaluation of Genetron TERT PCR Kit in Glioma Patients · completed
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT05343832 (US National Library of Medicine, public domain)
- Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by Genetron Health
- Last refreshed: 11 May 2022
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT05343832.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing